This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Combined Buprenorphine and Behavioral Treatment With and Without Contingent Reinforcement on Opioid and Cocaine Abstinence. - 22

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by:
University of Vermont Identifier:
First received: September 20, 1999
Last updated: June 2, 2015
Last verified: April 1999
The purpose of this study is to test combined buprenorphine and behavioral treatment with and without contingent reinforcement on opioid and cocaine abstinence.

Condition Intervention Phase
Cocaine-Related Disorders Opioid-Related Disorders Drug: Buprenorphine Phase 2

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: Combined Buprenorphine and Behavioral Treatment Without Contingent Reinforcement

Resource links provided by NLM:

Further study details as provided by University of Vermont:

Primary Outcome Measures:
  • Drug use
  • Retention
  • Weeks abstinent
  • Weeks continuous abstinence
  • Overall treatment outcome
  • Opioid dependence and psychiatric status

Estimated Enrollment: 0
Study Start Date: April 1999

Ages Eligible for Study:   23 Years to 47 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Please contact site for information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000240

United States, Vermont
Treatment Research Center
Burlington, Vermont, United States, 05401
Sponsors and Collaborators
University of Vermont
National Institute on Drug Abuse (NIDA)
Principal Investigator: Warren Bickel, Ph.D. University of Vermont
  More Information Identifier: NCT00000240     History of Changes
Other Study ID Numbers: NIDA-06969-22
R01DA006969 ( U.S. NIH Grant/Contract )
Study First Received: September 20, 1999
Last Updated: June 2, 2015

Additional relevant MeSH terms:
Opioid-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists processed this record on August 16, 2017